Literature DB >> 187736

Carnitine-palmityl-transferase deficiency.

W J Cumming, M Hardy, P Hudgson, J Walls.   

Abstract

An increasing number of cases of myopathy due to disordered lipid metabolism have recently been recognised and these appear to fall into two contrasting clinical and biochemical categories. Some patients present with steadily prograssive proximal weakness which sometimes responds to steroid therapy and which is due to carnitine deficiency in skeletal muscle. In the second category, patients usually present with muscle cramps on exertion then followed by myoglobinuria without established proximal myopathy and their symptoms are associated with deficiency of carnitine palmityl transferase in skeletal muscle. In this paper we report a patient who has well-documented carnitine palmityl transferase deficiency, whose symptoms were triggered by violent exercise after fasting and in whom there was variable histochemical and ultrastructural evidence of lipid accumulation in muscle biopsy samples. Development of the patient's symptoms was suppressed by a high carbohydrate diet.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187736     DOI: 10.1016/0022-510x(76)90131-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

1.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

2.  Recurrent exertional rhabdomyolysis and stunted growth.

Authors:  R C Sengers; A M Stadhouders; J M Trijbels; H H Jaspar
Journal:  Eur J Pediatr       Date:  1978-09-08       Impact factor: 3.183

Review 3.  Therapy of mitochondrial disorders.

Authors:  H Przyrembel
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

4.  Myoglobinuria: the importance of reaching a firm diagnosis--a patient with defective fatty acid oxidation.

Authors:  C J Ellis; A G Dewhurst; M Cooper; D P Brenton; J R Dathan
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

5.  Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.

Authors:  Patrick Schöffski; Vincente Guillem; Margarita Garcia; Fernando Rivera; Josep Tabernero; Martin Cullell; Jose Antonio Lopez-Martin; Patricia Pollard; Herlinde Dumez; Xavier Garcia del Muro; Luis Paz-Ares
Journal:  Mar Drugs       Date:  2009-03-05       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.